Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03619837 · ClinicalTrials.gov registry record · Phase 4
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
A Phase 4 study of Hepatitis C and Transplantation Disease Transmission, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
- 6
- Study locations
NCT03619837: Completed Phase 4 study of Hepatitis C and Transplantation Disease Transmission, sponsored by University of California, San Francisco.
NCT03619837 is a Phase 4 study of Hepatitis C and Transplantation Disease Transmission that has completed, run by University of California, San Francisco. The registered enrollment target is 122 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03619837, a Phase 4 study of Hepatitis C and Transplantation Disease Transmission, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
- 6
- Study locations
Study Summary
In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with livers or kidneys from donors who do have HCV. Medications that are used to treat HCV will be given to the study subjects shortly after transplant to protect them from developing the problems HCV can cause to the liver.
Primary Outcome
The primary outcome was sustained virologic response, defined as HCV RNA below the lower limit of quantification 12 weeks after treatment completion (SVR12). Secondary outcomes included the proportion of patients with SVR24 defined as HCV RNA \< lower limit of quantification 24 weeks after the end of treatment; with viral relapse defined as HCV RNA \<LLOQ at end of treatment with subsequent quantifiable HCV RNA; and with on-treatment virologic breakthrough defined as \> 1 log increase in viral R
Conditions Studied
Interventions
- DRUG Sofosbuvir/Velpatasvir
- DRUG Sofosbuvir/Velpatasvir/Voxilaprevir
Study Locations (6)
Texas
- Baylor University Medical Center - Dallas - Dallas
- Houston Methodist Hospital - Houston
California
- University of California, San Francisco - San Francisco
Colorado
- University of Colorado Denver - Aurora
Georgia
- Piedmont Research Institute - Atlanta
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2018-07-15 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 4 |
What the finished NCT03619837 record still lists
NCT03619837 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Sofosbuvir/Velpatasvir is the first listed.
NCT03619837 lists 6 locations in 5 states (Texas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT03619837 about?
NCT03619837 is a clinical study titled "Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant". In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with livers or kidneys from donors who do have HCV. Medications that are used to treat HCV will be given to the study subjects shortly after transplant to protect them from developing the problems HCV can cause to ...
What is the current status of trial NCT03619837?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2018-07-15. Estimated completion is 2020-08-13.
What conditions does trial NCT03619837 study?
This clinical trial studies the following conditions: Hepatitis C, Transplantation Disease Transmission.
What interventions are being tested in trial NCT03619837?
The interventions under investigation include: Sofosbuvir/Velpatasvir (DRUG), Sofosbuvir/Velpatasvir/Voxilaprevir (DRUG).
Who is sponsoring clinical trial NCT03619837?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03619837 being conducted?
This trial has 6 study locations across California, Colorado, Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03619837's enrollment target sits among peer trials
122 49th of 106 higher than 58 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI